Navigation Links
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
Date:7/24/2008

1,997 1,653

Sales and marketing 5,827 5,229

General and administrative 1,662 1,651

Total operating expenses 9,486 8,533

Income from operations 4,017 4,483

Interest and other income (expense), net 462 499

Income before income taxes 4,479 4,982

Income tax provision 1,703 1,884

Net income $2,776 $3,098

Net income per share:

Basic net income per share $0.13 $0.15

Diluted net income per share $0.12 $0.14

Shares used in the calculation of net

income per share:

Weighted average common shares

outstanding - basic 21,735 21,311

Weighted average common shares

outstanding - diluted 22,398 22,102

ABAXIS, INC.

Condensed Balance Sheets

(Unaudited and in thousands)

June 30, March 31,

2008 2008

Current assets:

Cash and cash equivalents $23,031 $17,219

Short-term investments 6,991 6,991

Trade receivables, net 20,952 20,873

Inventories, net 18,358 18,657

Prepaid expenses 1,190 427

Net deferred tax asset - current 2,760 2,426

Total current assets 73,282 66,593

Lon
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
2. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
3. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2008)...Newswire-FirstCall/ -- Cell Therapeutics, Inc.,(CT...sent at three upcoming,investor conferences. The c...um in San Francisco in October, the 19th Annual Op... Annual Acumen BioFin Rodman & Renshaw,Healthcare ...he presentations will be webcast live with slides,...
(Date:10/10/2008)...Newswire-FirstCall/ -- Cell Therapeutics, Inc.,(CT... Company intends to,request a hearing with the NAS... for regaining compliance with NASDAQ Marketplace ...t value of listed securities of $50 million.,CTI r...AQ Stock Market LLC,on October 7, 2008 indicating ...
(Date:10/10/2008)... academia and industry reveal powerful effects of,... mammalian cell culture leading to a si...olo., Oct. 10 /- A recently published... & Developmental Biology,revealed that recombinant....Lacromin.com ) is a strong growth factor for prom...
(Date:10/10/2008)...10 /- Boston Scientific,Cor...ived approval from the,U.S. Food and Drug Administ...(R) Liberte(R) Paclitaxel-Eluting Coronary Stent S...te stent early next month in the United,States, fo...S(R),Expresss2(TM) Atom(TM) Paclitaxel-Eluting Cor...
Breaking Biology Technology:Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 3New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 3
...he business section of Sunday,s San Jose Mercury N...ff 35% ." , ,After several quarters of increasing ...illion into new businesses last quarter, down a th...ding to the MoneyTree Survey conducted by Pricewat...National Venture Capital Association. While a 35% ...
...dison, Wis. Governor Jim Doyle announced today o...r the state to maintain its leadership in the fiel...l research. The governor said that almost $750 mil...eral years, and he outlined a series of investment...ry on the UW-Madison campus. , Read the latest...
...he other day I went to a lecture on angel investin...ience raised his hand. He wanted to know whether t...s from Fond du Lac to Green Bay had enough entrep...nvestors. , ,When I heard this, I realized that th...nsins perception of itself. A number of Wisconsin-...
...or years, our firm has been touting the Bureau of ...oyees will leave the workforce for every new one e...e of ten million employees. , ,In an election cycl...ff-shoring is becoming de rigueur, these numbers s...st common arguments I hear refuting BLS statistics...
Other Biology Technology:Start-ups grow up 2Start-ups grow up 3Wisconsins governor unveils $750 million investment for stem cell and health research 2Wisconsin entrepreneurs need to self-promote like coastal rivals 2Wisconsin entrepreneurs need to self-promote like coastal rivals 3Wisconsin entrepreneurs need to self-promote like coastal rivals 4Wisconsin entrepreneurs need to self-promote like coastal rivals 5Wisconsin entrepreneurs need to self-promote like coastal rivals 6Talent shortage? Cmon. 2
(Date:10/10/2008)... in German . , DNA, the molecule that acts as...f life, is highly resistant against alteration by ... for its photostability presents some puzzling pro... four chemical bases that make up the DNA molecule... showing that DNA strands differ in their light se...
(Date:10/9/2008).... 9 /PRNewswire-FirstCall/ -- Synaptics(R),Incorpo...an interface,solutions for mobile computing, commu...day that it will report financial results for the ...23, 2008 after the close of market. The,company wi...ts and,investors at 2:00 p.m. PT (5:00 p.m. ET) du...
(Date:10/9/2008)...ed life,s ability to respond? Biodiversity in a Wa...f the journal, Science , illustrates that cross-d...ropical Research Institute in Panama clearly infor...region of rainforest and coral reefs, the tropics ...rming. Some disagree, arguing that tropical organi...
(Date:10/9/2008)...years, the number of patients with compromised imm...tients such as these require a unique set of healt...thing from the etiology and degree of immune suppr...tus. A new text from ASM Press, Diagnostic Microbi...ide range of approaches and challenges to infectio...
Breaking Biology News(10 mins):Can genetic information be controlled by light? 2Synaptics to Report First Quarter Results on October 23 2Smithsonian perspective: Biodiversity in a warmer world 2Text focuses on diagnosing infections in immunocompromised patients 2Threshold for bowel surgery may be too high warn experts 5076 1Threshold for bowel surgery may be too high warn experts 5076 2MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 1MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 2MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 3MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 4Anesiva Announces Upcoming Webcasts and Conference Participation 5068 1Anesiva Announces Upcoming Webcasts and Conference Participation 5068 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 1King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 4King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 5King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 6
...trospective study in the Canadian Medical Associat...ularly boys, are about twice as likely as the tota...m an injury. , Brison and colleagues collected and...ries to young children to determine rates, identif...ms and ranches. They found that children 1? years ...
...e compounds could be a key component for cheaper, ...a Richards in Chemistry & Industry magazine. ,...each year, of which nearly 2,700 die, according to...ut is unsuitable for most patients, and liver tumo...an Cancer Society estimates that 18,510 new cases ...
...ers have found that the neurotransmitter serotonin...promote lasting, quality sleep in an animal model ...ntral to the lives of most animals, the proper reg... , The findings are reported by Quan Yuan, Willia...nnsylvania, and appear in the June 6th issue of Cu...
...e lovers, beware. Each year 20 percent of the caca...o plant diseases, but even greater losses would oc...eases are the most important constraints to cacao ...d,s confectionary trades," said Randy Ploetz, plan..., Homestead, FL. Currently, 4 million metric tons ...
Other Biology News:
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies.
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)
PP2B-Abeta (C-20)
... intensely fluorescent and highly photostable Fluo...se in a variety of applications requiring probes t...otein- and other macromolecule-labeled microsphere...bind to non-target surfaces in some applications. ...
Biology Products: